论文部分内容阅读
目的:探索微管相关蛋白2(microtubule-associated protein 2,MAP2)与微管相关蛋白1B(microtubule-associated protein 1B,MAP1B)在预测胰腺神经内分泌肿瘤(pancreatic neuroendocrine tumors,PNETs)患者预后中的意义。方法:收集1999年12月至2016年12月来自于北京协和医院、中山大学附属第一医院、复旦大学上海癌症中心和Cedars-Sinai医学中心(洛杉矶)193例患者的193个原发肿瘤标本。免疫组织化学染色法分别检测193例、120例PNETs组织中MAP2、MAP1B的表达,随后分析蛋白表达与患者临床病理特征及预后的关系。结果:MAP2和MAP1B在PNETs患者中的阳性率分别为45.6%(88/193)和64.2%(77/120)。MAP2表达阳性的患者的总生存好于阴性患者(P=0.012)。另外,MAP2阳性Ⅱ、Ⅲ期患者的总生存也优于阴性者(P=0.017)。然而,MAP1B的表达与肿瘤大小、转移、肿瘤组织学分级、临床分期、总生存、无病生存均无相关性(P>0.05)。结论:MAP2为潜在的预测PNETs患者预后的指标。
Objective: To explore the significance of microtubule-associated protein 2 (MAP2) and microtubule-associated protein 1B (MAP1B) in prognosis of patients with pancreatic neuroendocrine tumors (PNETs) . METHODS: A total of 193 primary tumor samples from 193 patients with Peking Union Medical College Hospital, First Affiliated Hospital of Sun Yat-sen University, Shanghai Cancer Center Fudan University and Cedars-Sinai Medical Center (Los Angeles) from December 1999 to December 2016 were collected. Immunohistochemical staining was used to detect the expression of MAP2 and MAP1B in 193 cases and 120 cases of PNETs. The relationship between the protein expression and the clinicopathological features and prognosis was analyzed. Results: The positive rates of MAP2 and MAP1B in PNETs were 45.6% (88/193) and 64.2% (77/120), respectively. Patients with positive MAP2 expression had a better overall survival than negative patients (P = 0.012). In addition, the overall survival of patients with MAP2 positive stage II and III was also better than that of negative (P = 0.017). However, MAP1B expression was not associated with tumor size, metastasis, tumor histological grade, clinical stage, overall survival, disease-free survival (P> 0.05). Conclusion: MAP2 is a potential predictor of prognosis in patients with PNETs.